<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795296</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-013-SH-GC-101</org_study_id>
    <nct_id>NCT05795296</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer</brief_title>
  <official_title>Clinical Study of Fruquintinib in Combination With Sintilimab as a First-line Therapy in Gastric Adenocarcinoma/Adenocarcinoma of Esophagogastric Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to explore the efficacy and safety in patients with&#xD;
      gastric adenocarcinoma or adenocarcinoma of esophagogastric junction. The main questions it&#xD;
      aims to answer are:&#xD;
&#xD;
        -  Does this therapy have a promising efficacy?&#xD;
&#xD;
        -  Does this therapy have a manageable toxicity? Participants will receive fruquintinib&#xD;
           plus sintilimab as first-line therapy for gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2022</start_date>
  <completion_date type="Anticipated">August 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of patients with complete response or partial response, using RECIST v 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>Time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of patients with complete response, partial response or stable disease, using RECIST v 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse event assessed according to CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>Fruquintinib+Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fruquintinib: 5mg po, d1-d14, q3w&#xD;
Sintilimab: 200mg ivgtt, d1, q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib</intervention_name>
    <description>Fruquintinib: 5mg po, d1-d14, q3w</description>
    <arm_group_label>Fruquintinib+Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Sintilimab: 200mg ivgtt, d1, q3w</description>
    <arm_group_label>Fruquintinib+Sintilimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological confirmed advanced, recurrent, of metastatic gastric&#xD;
             adenocarcinoma or adenocarcinoma of esophagogastric junction;&#xD;
&#xD;
          -  ECOG PS: 0-2;&#xD;
&#xD;
          -  Adequate hepatic, renal, heart, and hematologic functions;&#xD;
&#xD;
          -  At least one measurable lesion (according to RECIST1.1);&#xD;
&#xD;
          -  Haven't received any systematic treatment for the cancer involved;&#xD;
&#xD;
          -  Expected survival &gt; 12 weeks;&#xD;
&#xD;
          -  Contraception until 6 months after the study termination;&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Her-2-positive gastric cancer, or exposed to any immune checkpoint inhibitor;&#xD;
&#xD;
          -  Participated in another study;&#xD;
&#xD;
          -  Immunodeficiency;&#xD;
&#xD;
          -  Received allograftï¼›&#xD;
&#xD;
          -  Unmanageable hypertension, diabetes, or coronary disease;&#xD;
&#xD;
          -  Have difficulty in taking medicine, or active bleeding;&#xD;
&#xD;
          -  Pulmonary tuberculosis, or interstitial lung disease that needs steroid therapy;&#xD;
&#xD;
          -  Infection of HIV, HBV, HCV, or other unmanageable infection;&#xD;
&#xD;
          -  Other malignant tumor history;&#xD;
&#xD;
          -  Allergic to the test drug;&#xD;
&#xD;
          -  Other diseases which will affect the results of this study;&#xD;
&#xD;
          -  Received resection of stomach;&#xD;
&#xD;
          -  Taking anti-tumor traditional Chinese Medicine;&#xD;
&#xD;
          -  Severe active bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuiping Tu</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 31, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Shuiping Tu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

